Our Company
We are a privately held, late clinical-stage biopharmaceutical company that is focused on identifying and developing therapies for patients suffering from serious gastrointestinal (GI) diseases.
We are developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy patients’ unmet needs and overall disease burden
The lack of innovation and limited treatment options for patients with chronic and debilitating GI disorders present us with a significant opportunity.
